CN109045308A - A kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method - Google Patents
A kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method Download PDFInfo
- Publication number
- CN109045308A CN109045308A CN201811197924.XA CN201811197924A CN109045308A CN 109045308 A CN109045308 A CN 109045308A CN 201811197924 A CN201811197924 A CN 201811197924A CN 109045308 A CN109045308 A CN 109045308A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- carbon nanotube
- hericium erinaceum
- erinaceum polysaccharide
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
- Carbon And Carbon Compounds (AREA)
Abstract
The present invention provides a kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method, and hericium erinaceum polysaccharide is loaded on chitosan-carboxylation multi-walled carbon nanotube, and the carbon nanotube after modification can reduce its toxicity, increases the application on organism.Drugloading rate and encapsulation rate are high.Cross-film ability is strong in cell, is that application of the functionalized carbon nano-tube on drug carrier material is provided fundamental basis.
Description
Technical field
The invention belongs to field of biotechnology, and in particular to a kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation side
Method.
Background technique
Nowadays Nano medication is a focus on research direction of biomedicine field, and it is desirable to Nano medications to keep away
The disadvantage for exempting from existing drug improves the curative effect of drug.In the past few decades, people have synthesized some nano-carriers such as lipid
Body, micella, Nano particles of silicon dioxide, carbon nanotube etc..Largely modern research shows that hericium erinaceum polysaccharide has anti-oxidant, enhancing
Immunity, anti-aging, it is hypoglycemic the effects of, but bioavailability is not high, and effective component is lost serious.This research is poly- using shell
Sugar/carbon nanotube modifies hericium erinaceum polysaccharide, because carbon nanotube has a ultra-light-weight, inner hollow space, high surface area
Structure, so that carbon nanotube can be good at entrapped drug, and its strongest ability is the cross-film ability of cell, so that carbon nanometer
Pipe can become the ideal carrier during a kind of medicament transport.Untreated carbon nanotube biological compatibility is poor, has potential
Toxicity.And chitosan possesses good biocompatibility, toxicity is lower, easily prepared.By chitosan to carbon nanotube into
Row functional modification improves the water solubility of carbon nanotube, and then using hericium erinaceum polysaccharide as model drug, discovery is received with chitosan carbon
Mitron carries hericium erinaceum polysaccharide, and discovery can enhance its drugloading rate and encapsulation rate compared with traditional polysaccharide method for making Nano, is functionalization
Application of the carbon nanotube on drug carrier material is provided fundamental basis.
The research for carrying medicine about hericium erinaceum polysaccharide at present has two: the effective elements of the medicine is in carbon nanotube in 1.
Upper research is seldom.This research uses hericium erinaceum polysaccharide, has filled up the blank on Chinese medicine.After 2. drug is loaded on carrier
Drugloading rate it is low.3. not carrying out follow-up study to it after study on the carrier success.
Summary of the invention
The purpose of the present invention is to provide a kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation methods.
To achieve the above object, the present invention adopts the following technical scheme:
A kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method, comprising the following steps:
(1) chitosan-carboxylation multi-walled carbon nanotube preparation；
1) 0.2 g of chitosan CS is weighed, with 0.1 mol/L acetic acid constant volume, 100 mL, 30 min of ultrasound；
2) 50 mg multi-walled carbon nanotubes (MWCNTs), 30 min of ultrasound are added；
3) 40 ml 1mg/mL TPP solution, 5 h of magnetic agitation are dropped evenly；
4) 13000 rpm of mixture, 30 min is centrifugated, is cleaned 3 times with ultrapure water；
5) freeze-drying is further tested with obtaining chitosan-carboxylation multi-walled carbon nanotube (CS-MWCNTs) powder.
(2) load of hericium erinaceum polysaccharide.
1) 5 mg chitosans-carboxylation multi-walled carbon nanotube (CS-MWCNTs) is accurately weighed, is dissolved in 8 mL deionizations,
5 min of ultrasonic disperse；
2) 20 mg hericium erinaceum polysaccharides separately are weighed, is added in step (1) solution with after deionized water dissolving, ultrasonic mixing dispersion 30
min；Guarantee chitosan-carboxylation multi-walled carbon nanotube (CS-MWCNTs) is 0.5 mg/mL, and hericium erinaceum polysaccharide is 2.0 mg/mL；
3) 13000 rpm of mixture, 30 min is centrifugated, is cleaned 3 times with ultrapure water；
4) supernatant sugar concentration is surveyed, chitosan/carbon nanotube/hericium erinaceum polysaccharide (CS-MWCNTs-Hep) mixture freeze-drying is spare.
The present invention has the advantages that
1. the carbon nanotube after modification can reduce its toxicity, increase the application on organism.
2. drugloading rate and encapsulation rate are high.
3. cross-film ability is strong in cell, the application for being functionalized carbon nano-tube on drug carrier material provides theory
Basis.
Specific embodiment
Embodiment 1
A kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method, comprising the following steps:
(1) chitosan-carboxylation multi-walled carbon nanotube preparation；
1) 0.2 g of CS is weighed, with 0.1 mol/L acetic acid constant volume, 100 mL, 30 min of ultrasound；
2) 50 mg MWCNTs, 30 min of ultrasound are added；
3) 40 mL, 1 mg/mL TPP solution, 5 h of magnetic agitation are dropped evenly；
4) 13000 rpm of mixture, 30 min is centrifugated, is cleaned 3 times with ultrapure water；
5) freeze-drying is further tested with obtaining CS-MWCNTs powder.
(2) load of hericium erinaceum polysaccharide:
1) 5 mg CS-MWCNTs are accurately weighed, are dissolved in 8 mL deionizations, 5 min of ultrasonic disperse；
2) 20 mg hericium erinaceum polysaccharides separately are weighed, is added in step (1) solution with after deionized water dissolving, ultrasonic mixing dispersion 30
min；Guarantee CS-MWCNTs is 0.5 mg/mL, and hericium erinaceum polysaccharide is 2.0 mg/mL；
3) 13000 rpm of mixture, 30 min is centrifugated, is cleaned 3 times with ultrapure water；
4) supernatant sugar concentration is surveyed, the freeze-drying of CS-MWCNTs-Hep mixture is spare.
CS-MWCNTs modification hericium erinaceum polysaccharide becomes larger relative to original carbon nanotubes zeta current potential, and polysaccharide solution is more steady
It is fixed.Relative to other nanometer of polysaccharide, CS-MWCNTs-Hep has drugloading rate big, the high feature of encapsulation rate, and experiment surveys it and carries medicine
Rate is 41.7 % and encapsulation rate is 98.60 %.CS-MWCNTs-Hep has proliferation function when acting on IPEC-J2 cell, simultaneously
It can reduce by H2O2Caused apoptosis；In zoopery, compared with hericium erinaceum polysaccharide, polysaccharide can be significantly increased and answered immune
The protective effect for swashing mouse, improves the immunity of mouse.
The foregoing is merely presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification, is all covered by the present invention.
Claims (3)
1. a kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method, it is characterised in that: the following steps are included:
(1) chitosan-carboxylation multi-walled carbon nanotube preparation；
(2) load of hericium erinaceum polysaccharide.
2. a kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method according to claim 1, it is characterised in that:
The preparation of the chitosan-carboxylation multi-walled carbon nanotube are as follows:
(1) 0.2 g of chitosan is weighed, with 0.1 mol/L acetic acid constant volume, 100 mL, 30 min of ultrasound；
(2) 50 mg multi-walled carbon nanotubes, 30 min of ultrasound are added；
(3) 40 ml 1mg/mL TPP solution, 5 h of magnetic agitation are dropped evenly；
(4) mixture is centrifugated, is cleaned 3 times with ultrapure water；
(5) freeze-drying is further tested with obtaining chitosan-carboxylation multi-wall carbon nano-tube pipe powder.
3. a kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method according to claim 1, it is characterised in that:
The load step of hericium erinaceum polysaccharide are as follows:
(1) 5 mg chitosans-carboxylation multi-walled carbon nanotube is accurately weighed, is dissolved in 8 mL deionizations, 5 min of ultrasonic disperse；
(2) 20 mg hericium erinaceum polysaccharides separately are weighed, with after deionized water dissolving plus in step (1) solution, ultrasonic mixing disperses 30
min；Guarantee chitosan-carboxylation multi-walled carbon nanotube is 0.5 mg/mL, and hericium erinaceum polysaccharide is 2.0 mg/mL；
(3) mixture is centrifugated, is cleaned 3 times with ultrapure water；
(4) supernatant sugar concentration is surveyed, the freeze-drying of CS-MWCNTs-Hep mixture is spare.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811197924.XA CN109045308B (en) | 2018-10-15 | 2018-10-15 | Preparation method of chitosan/carbon nano tube/hericium erinaceus polysaccharide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811197924.XA CN109045308B (en) | 2018-10-15 | 2018-10-15 | Preparation method of chitosan/carbon nano tube/hericium erinaceus polysaccharide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109045308A true CN109045308A (en) | 2018-12-21 |
| CN109045308B CN109045308B (en) | 2021-11-23 |
Family
ID=64764019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811197924.XA Active CN109045308B (en) | 2018-10-15 | 2018-10-15 | Preparation method of chitosan/carbon nano tube/hericium erinaceus polysaccharide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109045308B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110064058A (en) * | 2019-05-09 | 2019-07-30 | 青岛科技大学 | A kind of preparation method of aspirin/chitosan-modified carbon nanotube drug delivery system |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005206655A (en) * | 2004-01-21 | 2005-08-04 | Kawamura Inst Of Chem Res | Polyion complex composite and its preparation method |
| CN102274510A (en) * | 2011-07-15 | 2011-12-14 | 华南理工大学 | Preparation method of carbon nanotube-chitosan-phycocyanin nanoparticles |
| CN105457032A (en) * | 2014-08-11 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | Cancer stem cell-targeting carbon nano-tube-salinomycin drug delivery system, preparation method and uses thereof |
| CN106390952A (en) * | 2016-10-13 | 2017-02-15 | 合众（佛山）化工有限公司 | Novel carbon nanotube composite hydrogel and preparation method thereof |
-
2018
- 2018-10-15 CN CN201811197924.XA patent/CN109045308B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005206655A (en) * | 2004-01-21 | 2005-08-04 | Kawamura Inst Of Chem Res | Polyion complex composite and its preparation method |
| CN102274510A (en) * | 2011-07-15 | 2011-12-14 | 华南理工大学 | Preparation method of carbon nanotube-chitosan-phycocyanin nanoparticles |
| CN105457032A (en) * | 2014-08-11 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | Cancer stem cell-targeting carbon nano-tube-salinomycin drug delivery system, preparation method and uses thereof |
| CN106390952A (en) * | 2016-10-13 | 2017-02-15 | 合众（佛山）化工有限公司 | Novel carbon nanotube composite hydrogel and preparation method thereof |
Non-Patent Citations (7)
| Title |
|---|
| CUIYUN LI等: "Highly biocompatible multi-walled carbon nanotube-chitosan nanoparticle hybrids as protein carriers", 《ACTA BIOMATERIALIA》 * |
| ZHE REN等: "Multi-walled carbon nanotube polysaccharide modified Hericium erinaceus polysaccharide as an adjuvant to extend immune responses", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
| ZHE REN等: "Optimization of Hericium erinaceus polysaccharide-loaded Poly (lactic-co-glycolicacid) nanoparticles by RSM and its absorption in Caco-2 cell monolayers", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
| ZHE REN等: "Preparation, characterization and controlled-release property of CS crosslinked MWCNT based on Hericium erinaceus polysaccharides", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
| 刘爱红等: "壳聚糖对碳纳米管的表面修饰", 《硅酸盐学报》 * |
| 邓亚利等: "羧基化碳纳米管负载羟基喜树碱的制备、表征及肠吸收特性考察", 《中国实验方剂学杂志》 * |
| 陈新瑶等: "猴头菇多糖对氧化应激的IPEC-J2细胞抗氧化能力及紧密连接蛋白ZO-1的影响", 《畜牧兽医学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110064058A (en) * | 2019-05-09 | 2019-07-30 | 青岛科技大学 | A kind of preparation method of aspirin/chitosan-modified carbon nanotube drug delivery system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109045308B (en) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108046276B (en) | A kind of polyethyleneglycol modified preparation of mesoporous silica nano-particle of carboxy blocking and application thereof | |
| Xie et al. | Hybrid nanoparticles for drug delivery and bioimaging: mesoporous silica nanoparticles functionalized with carboxyl groups and a near-infrared fluorescent dye | |
| CN102895258A (en) | Pleurotus tuber-regium polysaccharide functionalized nanometer selenium hydrosol having anti-tumor activity and preparation method thereof | |
| CN104263358A (en) | Magnetic-fluorescent difunctional graphene oxide nanocomposite and preparation method thereof | |
| JP5646505B2 (en) | Method for imparting water solubility or water dispersibility to hydrophobic cluster compounds | |
| CN108079019A (en) | Water-soluble fullerene nano material and preparation method thereof and anti-oxidant application | |
| Meng et al. | Xanthoceraside hollow gold nanoparticles, green pharmaceutics preparation for poorly water-soluble natural anti-AD medicine | |
| CN109045308A (en) | A kind of chitosan/carbon nanotube/hericium erinaceum polysaccharide preparation method | |
| Hernandez-Adame et al. | Biosynthesis of β-d-glucan‑gold nanoparticles, cytotoxicity and oxidative stress in mouse splenocytes | |
| CN105055372A (en) | Method for preparing carboxymethyl konjac glucomannan nano drug carrying microspheres | |
| CN101780282B (en) | Chitosan-carrying mitomycin nano targeting preparation and preparation method thereof | |
| Ghasemishahrestani et al. | Tunable synthesis of gelatin nanoparticles employing sophorolipid and plant extract, a promising drug carrier | |
| CN101040869A (en) | Nanometer elemental selenium coupled with liquid amino acid and the method for preparing and preserving the same | |
| CN110542671B (en) | Organic two-photon fluorescent probe, preparation and application thereof | |
| CN107814376A (en) | A kind of titania-doped coated carbon nano-tube composite material of selenium | |
| Lakshmi Narayanan et al. | Preparation and characterization of gold nanoparticles in chitosan suspension by one-pot chemical reduction method | |
| CN115028754B (en) | Sulfated hericium erinaceus fruiting body beta-glucan, sulfated beta-glucan-chitosan nanoparticle and preparation method and application thereof | |
| Yeniyurt et al. | Fmoc-PEG coated single-wall carbon nanotube carriers by non-covalent functionalization: an experimental and molecular dynamics study | |
| Ren et al. | Preparation, characterization and controlled-release property of CS crosslinked MWCNT based on Hericium erinaceus polysaccharides | |
| Song et al. | Preparation and evaluation of insulin-loaded nanoparticles based on hydroxypropyl-β-cyclodextrin modified carboxymethyl chitosan for oral delivery | |
| CN101756209A (en) | Method for preparing nano sea cucumber royal jelly | |
| CN114522150A (en) | Preparation method and application of pH-sensitive plant microcapsule nano extruder | |
| CN108990973B (en) | Graphene oxide/chitosan quaternary ammonium salt composite material and preparation method and application thereof | |
| Venugopal et al. | Targeted delivery of silymarin to liver cells by galactosylated nanoparticles: in‐vitro & in‐vivo evaluation studies | |
| CN108067170A (en) | A kind of leprosy grape fruit powder injection ionization embedding equipment and its embedding method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |